Mannitol Cooper

Mannitol, the active ingredient in Mannitol Cooper, is an osmotic diuretic presented as an injection solution for intravenous use. It reduces intracranial pressure, lowers intraocular pressure, and offers renal protection during nephrotoxic procedures. Mannitol Cooper is supplied in a sterile liquid form that complies with EU pharmaceutical standards and is intended for use under medical supervision.

GNH USA supplies Mannitol Cooper as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Mannitol is used in clinical settings to manage conditions where fluid shifts and pressure reduction are required.

- Intracranial hypertension: lowers elevated intracranial pressure to prevent brain herniation. - Intraocular hypertension: reduces intraocular pressure in acute glaucoma emergencies. - Renal protection during nephrotoxic procedures: minimizes kidney injury during contrast imaging or surgery. - Acute renal failure (oliguric phase): promotes diuresis to aid fluid balance.

Mannitol may cause a range of adverse reactions, ranging from mild to severe.

Common Side Effects: - Headache: transient discomfort often related to rapid fluid shifts. - Nausea and vomiting: gastrointestinal upset following infusion. - Electrolyte imbalance: changes in sodium or potassium levels.

Serious or Rare Side Effects: - Pulmonary edema: fluid accumulation in the lungs, requiring immediate medical attention. - Severe hyponatremia: dangerously low blood sodium concentration. - Anaphylactic reaction: rare hypersensitivity that can be life‑threatening. - Cardiac arrhythmia: irregular heart rhythm due to electrolyte disturbances.

Mannitol administration requires careful monitoring and specific safety measures.

- Renal function monitoring: assess creatinine and urine output before and during therapy. - Electrolyte monitoring: check serum sodium, potassium, and osmolality regularly. - Cardiovascular status: observe blood pressure and heart rate for hypotension or overload. - Use in heart failure: avoid rapid infusion in patients with compromised cardiac function. - Infusion rate: administer over the recommended period to reduce risk of sudden fluid shifts. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Loop diuretics: may exacerbate electrolyte loss and dehydration. - ACE inhibitors: increased risk of hypotension and renal impairment. - Lithium: altered renal clearance can raise lithium levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce the diuretic effect of mannitol. - Anticoagulants: volume changes can affect bleeding risk. - Vasopressors: may require dose adjustments due to altered vascular tone.